Plain-English translation of NCT07587229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are building a new test that uses genetic patterns in tumors to predict whether a patient's gastric cancer will respond well to 5-FU-based chemotherapy. This test could help doctors decide which patients are most likely to benefit from this treatment after surgery. The study involves analyzing tumor tissue samples that have already been removed during surgery.
Right now, doctors cannot reliably predict which gastric cancer patients will respond well to chemotherapy before starting treatment. This test could help identify patients who are more likely to benefit from the medication, allowing doctors to make better treatment decisions and potentially spare some patients from ineffective therapy.
You likely qualify if…
You likely don't qualify if…
You would not undergo any new procedures or treatments. Instead, researchers would use tumor tissue that was already removed during your cancer surgery to perform genetic testing. Your medical records would also be reviewed to track whether your cancer returned within three years after your treatment. The study simply involves analyzing existing samples and information — no additional visits or medications required.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Enrollment target
~329 participants
Started
May 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ajay Goel
City of Hope Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.